The mechanisms of tolerance in antidepressant action

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 35, Issue 7, 2011, Pages 1593-1602

  Fava, Giovanni A ^a,b   Offidani, Emanuela ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

Antidepressant drugs; Oppositional tolerance; Relapse; Resistance; Switch; Withdrawal syndrome

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CLOMIPRAMINE; CLOZAPINE; DULOXETINE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MOOD STABILIZER; NORTRIPTYLINE; OXAPROTILINE; PLACEBO; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN 2 RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ARTICLE; BIPOLAR DISORDER; CHRONIC DISEASE; COGNITION; COGNITIVE THERAPY; DISEASE DURATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG EXPOSURE; DRUG INTERMITTENT THERAPY; DRUG SENSITIVITY; DRUG SENSITIZATION; DRUG SUBSTITUTION; DRUG TOLERANCE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INTERMETHOD COMPARISON; LONG TERM CARE; LOW DRUG DOSE; MAINTENANCE THERAPY; MAJOR DEPRESSION; MANIA; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PATIENT ATTITUDE; PATIENT COMPLIANCE; PHARMACODYNAMICS; PROTEIN FUNCTION; RECURRENT DISEASE; RELAPSE; REMISSION; TREATMENT DURATION; WITHDRAWAL SYNDROME;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DRUG TOLERANCE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE;

EID: 79953761059     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2010.07.026     Document Type: Article

References (139)

1. Akiskal H.S., Djenderedjian A.T., Rosenthal R.H., Khani M.K. Cyclothymic disorder: validating criteria for inclusion in the bipolar affective group. Am J Psychiatry 1977, 134:1227-1233.
2. Amsterdam J.D., Shults J. Does tachyphylaxis occur after repeated antidepressant exposure in patients with Bipolar II major depressive episode?. J Affect Disord 2009, 115:234-240.
3. Amsterdam J.D., Williams D., Michelson D., Adler L.A., Dunner D.L., Nierenberg A.A., et al. Tachyphylaxis after repeated antidepressant drug exposure in patients with recurrent major depressive disorder. Neuropsychobiology 2009, 59:227-233.
4. Andrade C. Antidepressant-withdrawal mania. J Clin Psychiatry 2004, 15:987-993.
5. Angst J. Switch from depression to mania. A record study of decades between 1920 and 1982. Psychopathology 1985, 18:140-155.
6. Antelman S.M., Gershon S. Clinical application of time-dependent sensitization to antidepressant therapy. Prog Neuropsychopharmacol Biol Psychiatry 1998, 22:65-78.
7. Aronson T.A. Treatment emergent depression with antidepressants in panic disorder. Comp Psychiatry 1989, 30:267-271.
8. Azorin J.M., Kaladjian A., Adida M., Hantouche E.G., Hameg A., Lancrenon S., et al. Factors associated with rapid cycling in bipolar I manic patients: findings from a French national study. CNS Spectr 2008, 13:780-787.
9. Bader C.D., Dunner D.L. Antidepressant-induced hypomania in treatment-resistant depression. J Psychiatr Pract 2007, 13:233-237.
10. Baker M.W., Croll R.P. Modulation of in vivo neuronal sprouting by serotonin in the adult CNS of the snail. Cell Mol Neurobiol 1996, 16:561-576.
11. Baldessarini R.J., Ghaemi S.N., Viguera A.C. Tolerance in antidepressant treatment. Psychother Psychosom 2002, 71:177-179.
12. Baldessarini R.J. Risks and implications of interrupting maintenance psychotropic drug therapy. Psychother Psychosom 1995, 63:137-141.
13. Baldwin D.S., Montgomery S.A., Nil R., Lader M. Discontinuation symptoms in depression and anxiety disorders. Int J Neuropsychopharmacol 2007, 10:73-84.
14. Baldwin R.C. Antidepressants in geriatric depression: what difference have they made?. Int Psychogeriatr 1995, 7:55-68.
15. Barlow D.H., Gorman J.M., Shear K.M., Woods S.W. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder. JAMA 2000, 285:2529-2536.
16. Bech P. The struggle for subtypes in primary and secondary depression and their mode-specific treatment or healing. Psychother Psychosom 2010;79:331-38.
17. Benazzi F. A therapeutic window with citalopram in a case of depression. Pharmacopsychiatry 1996, 29:42.
18. Benazzi F. Prevalence and clinical correlates of residual depressive symptoms in bipolar II disorder. Psychother Psychosom 2001, 70:232-238.
19. Berendsen H.G. Interactions between 5-hydroxytryptamine receptor subtypes. Pharmacol Ther 1995, 66:17-39.
20. Bhanji N.H., Chouinard G., Kolivakis T., Margolese H.C. Persistent tardive rebound panic disorder, rebound anxiety and insomnia following paroxetine withdrawal. Can J Clin Pharmacol 2006, 13:69-74.
21. Bockting C.L., ten Doesschate M.C., Spijker J., Spinhoven P., Koeter M.W. DELTA study group. Continuation and maintenance use of antidepressants in recurrent depression. Psychother Psychosom 2008, 77:17-26.
22. Brown T.A., Barlow D.H. Long-term outcome in cognitive behavioral treatment of panic disorder. J Consult Clin Psychol 1995, 63:754-765.
23. Brugha T.S., Bebbington P.E., MacCarthy B., Sturt E., Wykes T. Antidepressants may not assist recovery in practice. Acta Psychiatr Scand 1992, 86:5-11.
24. Byrne S.E., Rothschild A.J. Loss of antidepressant efficacy during maintenance therapy. J Clin Psychiatry 1998, 59:279-288.
25. Cain J.W. Poor response to fluoxetine. J Clin Psychiatry 1992, 53:272-277.
26. Carlson G.A., Finch S.J., Fochtmann L.J., Ye Q., Wang Q., Naz B., et al. Antidepressant-associated switches from depression to mania in severe bipolar disorder. Bipolar Disord 2007, 9:851-859.
27. Chouinard G., Chouinard V.A. Atypical antipsychotics. Psychother Psychosom 2008, 77:69-77.
28. Cohen B.M., Baldessarini R.J. Tolerance to therapeutic effects of antidepressants. Am J Psychiatry 1985, 142:489-490.
29. Corral M., Sivertz K., Jones B.D. Transient mood elevation associated with antidepressant drug decrease. Can J Psychiatry 1987, 32:764-767.
30. Coryell W., Solomon D., Leon A.C., Akiskal H.S., Keller M.B., Scheftner W.A., et al. Lithium discontinuation and subsequent effectiveness. Am J Psychiatry 1998, 895-898.
31. Coupland N.J., Bell C.J., Potokar J.P. Serotonin reuptake inhibitor withdrawal. J Clin Pharmacol 1996, 16:356-362.
32. Cusin C., Fava M., Amsterdam J.D., Quitkin F.M., Reimherr F.W., Beasley C.M., et al. Early symptomatic worsening during treatment with fluoxetine in major depressive disorder: prevalence and implications. J Clin Psychiatry 2007, 68:52-57.
33. Dawson R., Lavori P.W., Coryell W.N., Endicott J., Keller M.B. Maintenance strategies for unipolar depression. J Affect Disord 1998, 49:31-44.
34. Di Mascio A., Meyer R.E., Stifler L. Effects of imipramine on individuals varying in level of depression. Am J Psychiatry 1968, 127:55-58.
35. Diefenbach T.J., Sloley B.D., Goldberg J.I. Neurite branch development of an identified serotonergic neuron from embryonic Helisomer: evidence for autoregulation by serotonin. Dev Biol 1995, 167:282-293.
36. Dilsalver S.C. Heterocyclic antidepressant, monoamine oxidase inhibitor and neuroleptic withdrawal phenomena. Progr Neuropsychopharmacol Biol Psychiatry 1990, 14:137-161.
37. Donaldson S.R. Tolerance to phenelzine and subsequent refractory depression. J Clin Psychiatry 1989, 50:33-35.
38. El-Mallakh R.S., Gao Y., Briscoe B.T., Roberts J.R. Antidepressant induced tardive dysphoria. Psychother Psychosom 2011, 80:57-59.
39. El-Mallakh R.S., Ghaemi S.N., Sagduyu K., Thase M.E., Wisniewski S.R., Nierenberg A.A., et al. STEP-BD investigators. Antidepressant-associated chronic irritable dysphoria (ACID) in STEP-BD patients. J Affect Disord 2008, 111:372-377.
40. El-Mallakh R.S., Karippot A. Antidepressant-associated chronic irritable dysphoria (ACID) in bipolar disorder. J Affect Disord 2005, 84:267-272.
41. Faedda G.L., Tondo L., Baldessarini R.J., Suppes T., Tohen M. Outcome after rapid vs gradual discontinuation of lithium treatment in bipolar disorders. Arch Gen Psychiatry 1993, 50:448-455.
42. Fava G.A., Bernardi M., Tomba E., Rafanelli C. Effects of gradual discontinuation of selective serotonin reuptake inhibitors in panic disorder with agoraphobia. Int J Neuropsychopharmacol 2007, 10:835-838.
43. Fava G.A., Mangelli L. Mania associated with venlafaxine discontinuation. Int J Neurpsychopharmacol 2003, 6:89-90.
44. Fava G.A., Rafanelli C., Grandi S., Canestrari R., Morphy M.A. Six-year outcome for cognitive behavioral treatment of residual symptoms in major depression. Am J Psychiatry 1998, 155:1443-1445.
45. Fava G.A., Rafanelli C., Grandi S., Conti S., Ruini C., Mangelli L., et al. Long-term outcome of panic disorder with agoraphobia treated by exposure. Psychol Med 2001, 31:891-898.
46. Fava G.A., Tomba E., Grandi S. The road to recovery from depression: don't drive today with the yesterday's map. Psychother Psychosom 2007, 75:139-153.
47. Fava G.A. Can long term treatment with antidepressant drugs worsen the course of depression?. J Clin Psychiatry 2003, 64:123-133.
48. Fava G.A. Do antidepressant and antianxiety drugs increase chronicity in affective disorders?. Psychother Psychosom 1994, 61:125-131.
49. Fava G.A. The concept of recovery in affective disorders. Psychother Psychosom 1996, 65:2-13.
50. Fava M., Davidson K.G. Definition and epidemiology of treatment resistant depression. Psychiat Clin N Am 1996, 19:179-200.
51. Fava M., Detke M.J., Balestrieri M., Wang F., Raskin J., Perahia D. Management of depression relapse: re-initiation of duloxetine treatment or dose increase. J Psychiatry Res 2006, 40:328-336.
52. Fava M., Evins A.E., Dorer D.J., Schoenfeld D.D. The problem of the placebo response in clinical trials for psychiatric disorders. Psychother Psychosom 2003, 72:115-127.
53. Fava M., Rappe S.M., Pava J.A., Nierenberg A.A., Alpert J.E., Rosenbaum J.F. Relapse in patients on long-term fluoxetine treatment: response to increased fluoxetine dose. J Clin Psychiatry 1995, 56:52-55.
54. Fava M., Schmidt M.E., Zhang S., Gonzales J., Raute N.J., Judge R. Treatment approaches to major depressive disorder relapse. Part II. Re-initiation of antidepressant treatment. Psychother Psychosom 2002, 71:195-199.
55. Feldmann R.E., Sawa A., Seidler G.H. Causality of stem cell based neurogenesis and depression. J Psychiatr Res 2007, 41:713-723.
56. Fichtner C.G., Jobe T.H., Braun B.G. Does fluoxetine have a therapeutic window?. Lancet 1991, 338:520-521.
57. Fichtner C.G., Jobe T.H., Braun B.G. Possible therapeutic window for serotonin reuptake inhibitors. J Clin Psychiatry 1994, 55:36-37.
58. Franchini L., Rossini S., Bongiorno F., Spagnolo C., Smeraldi E., Zanardi R. Will a second prophylactic treatment with a higher dosage of the same antidepressant either prevent or delay new depressive episodes?. Psychiatry Res 2000, 96:81-85.
59. Friedman R.A., Mitchell J., Kocsis J.H. Retreatment for relapse following desipramine discontinuation in dysthymia. Am J Psychiatry 1995, 152:926-928.
60. Fux M., Taub M., Zohar J. Emergence of depressive symptoms during treatment for panic disorder with specific 5-hydroxytryptophan reuptake inhibitors. Acta Psychiatr Scand 1993, 88:235-237.
61. Gao K., Kemp D.E., Ganocy S.J., Muzina D.J., Xia G., Findling R.L., et al. Treatment-emergent mania/hypomania during antidepressant monotherapy in patients with rapid cycling bipolar disorder. Bipolar Disord 2008, 10:907-915.
62. Gardarsdottir H., Egberts T.C., Stolker J.J., Heerdink E.R. Duration of antidepressant drug treatment and its influence on risk of relapse/recurrence: immortal and neglected time bias. Am J Epidemiol 2009, 170:280-285.
63. Gardarsdottir H., van Geffen E.C., Stolker J.J., Egberts T.C., Heerdink E.R. Does the length of the first antidepressant treatment episode influence risk and time to a second episode?. J Clin Psychopharmacol 2009, 29:69-72.
64. Ghaemi S.N., Ostacher M.M., El-Mallakh R.S., Borrelli D., Baldassano C.F., Kelley M.E., et al. Antidepressant discontinuation in bipolar depression: a Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) randomized clinical trial of long-term effectiveness and safety. J Clin Psychiatry 2010, 71:372-380.
65. Ghaemi S.N., Wingo A.P., Filkowski M.A., Baldessarini R.J. Long-term antidepressant treatment in bipolar disorder: meta-analyses of benefits and risks. Acta Psychiatr Scand 2008, 118:347-356.
66. Goldberg J.F., Perlis R.H., Ghaemi S.N., Calabrese J.R., Bowden C.L., Wisniewski S., et al. Adjunctive antidepressant use and symptomatic recovery among bipolar depressed patients with concomitant manic symptoms: findings from the STEP-BD. Am J Psychiatry 2007, 164:1348-1355.
67. Goodwin F.K. The biology of recurrence. J Clin Psychiatry 1989, 50:40-44.
68. Gram L.F. Danish University Antidepressant Group (DUAG). Acute and continuation therapy in unipolar depression: observations from the run-in phase of a maintenance trial. Acta Psychiatr Scand 2008, 118:123-129.
69. Groves P.M., Thompson R.F. Habituation: a dual process theory. Psychol Rev 1970, 77:419-450.
70. Haddad P.M. Newer antidepressants and discontinuation syndrome. J Clin Psychiatry 1997, 58:17-21.
71. Harvey A.T., Silkey B.S., Kornstein S.G., Clary C.M. Acute worsening of chronic depression during a double-blind, randomized clinical trial of antidepressant efficacy: differences by sex and menopausal status. J Clin Psychiatry 2007, 68:951-958.
72. Healy D. Emergence of antidepressant induced suicidality. Prim Care Psychiatry 2000, 6:23-28.
73. Holsboer F., Barden N. Antidepressants and the hypothalamic-pituitary-adrenocortical regulation. End Rev 1996, 17:187-205.
74. Kantrowitz J.T., Tampi R.R. Risk of psychosis exacerbation by tricyclic antidepressants in unipolar major depressive disorder with psychotic features. J Affect Disord 2008, 106:279-284.
75. Katz M.M., Secunda S.K., Hirschfeld R.M., Koslow S.H. NIMH clinical research branch collaborative program on the psychobiology of depression. Arch Gen Psychiatry 1979, 36:765-771.
76. Kaymaz N., van Os J., Loonen A.J., Nolen W.A. Evidence that patients with single versus recurrent depressive episodes are differentially sensitive to treatment discontinuation: a meta-analysis of placebo-controlled randomized trials. J Clin Psychiatry 2008, 69:1423-1436.
77. Koob G.F., Cador M. Psychomotor stimulant sensitization: the corticotropin-releasing factor-steroid connection. Behav Pharmacol 1993, 4:351-354.
78. Koszewska I., Rybakowski J.K. Antidepressant-induced mood conversions in bipolar disorder: a retrospective study of tricyclic versus non-tricyclic antidepressant drugs. Neuropsychobiology 2009, 59:12-16.
79. Kramer J.C., Klein D.F., Fink M. Withdrawal symptoms following discontinuation of imipramine therapy. Am J Psychiatry 1961, 118:549-550.
80. Kukopulos A., Caliari B., Tundo A., Minnai G.P., Girardi P., Pani L., et al. Rapid cyclers, temperament, and antidepressants. Compr Psychiatry 1983, 24:249-258.
81. Kukopulos A., Reginaldi D., Laddomada P., Floris G., Serra G., Tondo L. Course of the manic-depressive cycle and changes caused by treatments. Pharmakopsychiatry 1980, 13:156-167.
82. Kurian B.T., Greer T.L., Trivedi M.H. Strategies to enhance the therapeutic efficacy of antidepressants: targeting residual symptoms. Expert Rev Neurother 2009, 9:975-984.
83. Lejoyeux M., Adès J., Mourad I., Solomon J., Dilsaver S. Antidepressant withdrawal syndrome: recognition, prevention and management. CNS Drugs 1996, 5:278-292.
84. Leonard B.E. Serotonin receptors and their function in sleep, anxiety disorders, and depression. Psychother Psychosom 1996, 65:66-75.
85. Leverich G.S., Altshuler L.L., Frye M.A., Suppes T., McElroy S.L., Keck P.E., et al. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry 2006, 163:232-239.
86. Leykin Y., Amsterdam J.D., DeRubeis R.J., Gallop R., Shelton R.C., Hollon S.D. Progressive resistance to a selective serotonin reuptake inhibitor but not to cognitive therapy in the treatment of major depression. J Consult Clin Psychol 2007, 75:267-276.
87. Lichtenberg P., Belmaker R.H. Subtyping major depressive disorder. Psychother Psychosom 2010, 79:131-135.
88. Lieb J., Balter A. Antidepressant tachyphylaxis. Med Hypotheses 1984, 15:279-291.
89. Maina G., Albert U., Bogetto F. Relapses after discontinuation of drug associated with increased resistance to treatment in obsessive-compulsive disorder. Int Clin Psychopharmacol 2001, 16:33-38.
90. Maj M., Pirozzi R., Magliano L. Non response to reinstituted lithium prophylaxis in previously responsive bipolar patients. Am J Psychiatry 1995, 152:1810-1811.
91. Mann J.J. Loss of antidepressant effect with long term monoamine oxidase inhibition. J Clin Psychopharmacol 1983, 3:363-366.
92. Marks I.M. Behavioral and drug treatments of phobic and obsessive-compulsive disorders. Psychother Psychosom 1986, 46:35-44.
93. McGrath P.J., Stewart J.W., Quitkin F.M., Chen Y., Alpert J.E., Nierenberg A.A., et al. Predictors of relapse in a prospective study of fluoxetine treatment of major depression. Am J Psychiatry 2006, 163:1542-1548.
94. Medawar C. The antidepressant web. Int J Risk Saf Med 1997, 10:75-126.
95. Michelson D., Amsterdam J., Apter J., Fava M., Londborg P., Tamura R., et al. Hormonal markers of stress response following interruption of selective serotonin reuptake inhibitor treatment. Psychoneuroendocrinology 2000, 25:169-177.
96. Michelson D., Fava M., Amsterdam J. Interruption of selective serotonin reuptake inhibitor treatment: double-blind, placebo controlled trial. Br J Psychiatry 2000, 176:363-368.
97. Molnar G., Gupta R.N. Plasma levels and tricyclic antidepressant therapy. Biopharm Drug Dispos 1980, 1:283-305.
98. Montgomery S.A., Huusom A.K., Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiol 2004, 50:57-64.
99. National Institute for Health and Clinical Excellence [NICE website]. Available at: Accessed April 27, 2010. http://www.nice.org.uk/nicemedia/live/12329/45896/45896.pdf.
100. Nelson J.C. The STAR*D study: a four course meal that leaves us wanting more. Am J Psychiatry 2006, 163:1864-1866.
101. Noyes R., Garvey H.J., Cook B.L. Follow-up study of patients with panic disorder and agoraphobia with panic attacks treated with tricyclic antidepressants. J Affect Disord 1989, 16:249-257.
102. Oliver J.S., Burrows G.D., Norman T.R. Discontinuation syndromes with selective serotonin reuptake inhibitors. CNS Drugs 1999, 12:171-177.
103. Otto M.W., Nierenberg A.A. Assay sensitivity, failed trials, and the conduct of science. Psychother Psychosom 2002, 71:241-243.
104. Otto M.W., Pollack M.H., Sabatino S.A. Maintenance of remission following cognitive behavior therapy for panic disorder. Behav Ther 1996, 27:473-482.
105. Pariante C., Miller A.H. Glucocorticoid receptors in major depression. Biol Psychiatry 2001, 49:391-404.
106. Perahia D.G., Kajdasz D.K., Desaiah D., Haddad P.M. Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder. J Affect Disord 2005, 89:207-212.
107. Pigott H.E., Leventhal A.M., Alter G.S., Boren J.J. Efficacy and effectiveness of antidepressants. Psychother Psychosom 2010, 79:267-279.
108. Pitchot W., Gonzales-Moreno A., Ansseau M. Therapeutic window for 5-HT reuptake inhibitors. Lancet 1992, 339:684.
109. Pope H.G., Jacobs A., Mialet J.P., Yurgelun-Todd D., Gruber S. Evidence for a sex-specific residual effect of cannabis on visuo-spatial memory. Psychother Psychosom 1997, 66:179-184.
110. Post R.M., Denicoff K.D., Leverich G.S., Frye M.A. Drug-induced switching in bipolar disorder. CNS Drugs 1997, 8:352-365.
111. Post R.M. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am J Psychiatry 1992, 149:999-1010.
112. Posternak M.A., Zimmerman M. Dual reuptake inhibitors incur lower rates of tachyphylaxis than selective serotonin reuptake inhibitors. J Clin Psychiatry 2005, 66:704-707.
113. Price J.S., Waller P.C., Wood S.M., Mackay A.V.P. A comparison of the post marketing safety of four selective serotonin reuptake inhibitors including the investigation of symptoms occurring on withdrawal. Br J Clin. Pharmacol 1996, 42:757-763.
114. Reimherr F.W., Amsterdam J.D., Quitkin F.M., Rosenbaum J.F., Fava M., Zajecka J., et al. Optimal length of continuation therapy in depression. Ann J Psychiatry 1998, 155:1247-1253.
115. Ritzmann R.F., Colbern D.L., Zimmermann E.G., Krivoy W. Neurohypophyseal hormones in tolerance and physical dependence. Pharm Ther 1984, 23:281-312.
116. Romano S., Goodman W., Tamura R., Gonzales J. Long-term treatment of obsessive-compulsive disorder after an acute response: a comparison of fluoxetine versus placebo. J Clin Psychopharmacol 2001, 21:46-52.
117. Rosa AR, Cruz N, Franco C, Haro JM, Bertsch J, Reed C, et al. Why do clinicians maintain antidepressants in some patients with acute mania? Hints from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM), a large naturalistic study. J Clin Psychiatry 2010;71:1000-6.
118. Rosenbaum J.F., Fava M., Hoog S.L., Ascroft R.C., Krebs W.B. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 1998, 44:77-87.
119. Rush A.J., Trivedi M.H., Wisniewski S.R., Nierenberg A.A., Stewart J.W., Warden D., et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps. Am J Psychiatry 2006, 163:1905-1917.
120. Schmidt M.E., Fava M., Zhang S., Gonzales J., Raute N.J., Judge R. Treatment approaches to major depressive disorder relapse. Part I: Dose increase. Psychother Psychosom 2002, 71:190-194.
121. Segal Z.V., Williams J.M., Teasdale J.D., Gemar M. A cognitive science perspective on kindling and episode sensitization in recurrent affective disorder. Psychol Med 1996, 26:371-380.
122. Sharma V. Loss of response to antidepressants and subsequent refractoriness. J Affect Disord 2001, 64:99-106.
123. Solomon D.A., Leon A.C., Mueller T.I., Coryell W., Teres J.J., Posternak M.A., et al. Tachyphylaxis in unipolar major depressive disorder. J Clin Psychiatry 2005, 66:283-290.
124. Sonino N., Fava G.A., Fallo F., Franceschetto A., Belluardo P., Boscaro M. Effect of the serotonin antagonists ritanserin and ketanserin in Cushing's disease. Pituitary 2000, 3:55-59.
125. Sonino N., Fava G.A. CNS drugs in Cushing's disease. Pathophysiological and therapeutic implications for mood disorders. Progr Neuropsychopharmacol Biol Psychiatry 2002, 26:763-770.
126. Stassen H.H., Delini.Stula A., Angst J. Time course of improvement under antidepressant treatment. Eur Neuropsychopharmacol 1993, 3:127-135.
127. Stewart J., Badiani A. Tolerance and sensitization to the behavioral effects of drugs. Behav Pharmacol 1993, 4:289-312.
128. Storosum J.G., van Zwieten B.J., Vermeulen H.D., Wohlfarth T., van den Brink W. Relapse and recurrence prevention in major depression: a critical review of placebo-controlled efficacy studies with special emphasis on methodological issues. Eur Psychiatry 2001, 16:327-335.
129. Therrien F., Markowitz J.S. Selective serotonin reuptake inhibitors and withdrawal symptoms: a review of literature. Hum Psychopharmacol 1997, 12:309-323.
130. Tondo L., Vázquez G., Baldessarini R.J. Mania associated with antidepressant treatment: comprehensive meta-analytic review. Acta Psychiatr Scand 2010, 121:404-414.
131. Turner E.H., Matthews A.M., Linardatos E., Tell R.A., Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008, 358:252-260.
132. Van Praag H.M. Faulty cortisol/serotonin interplay. Psychiatry Res 1996, 65:143-157.
133. Van Scheyen J.D. Recurrent vital depressions. Psychiatr Neurol Neurochir 1973, 76:93-112.
134. Viguera A.C., Baldessarini R.J., Friedberg J. Discontinuing antidepressant treatment in major depression. Harv Rev Psychiatry 1998, 5:293-306.
135. Wada K., Sasaki T., Jitsuiki H., Yoshimura Y., Erabi H., Hada Y., et al. Manic/hypomanic switch during acute antidepressant treatment for unipolar depression. J Clin Psychopharmacol 2006, 26:512-515.
136. Williams N., Simpson A.N., Simpson K., Nahas Z. Relapse rates with long-term antidepressant drug therapy: a meta-analysis. Hum Psychopharmacol 2009, 24:401-408.
137. Young A.M., Goudie A.J. Adaptive processes regulating tolerance to behavioral effects of drugs. Psychopharmacology 1995, Raven Press, New York. F.E. Bloom, D.J. Kupfer (Eds.).
138. Young L.T., Cooke R.G., Levitt A.J., Joffe R.T. Prior antidepressant treatment does not have an impact on response to desipramine treatment in major depression. Biol Psychiatry 1995, 38:410-412.
139. Zajecka J., Tracy K.A., Mitchell S. Discontinuation symptoms after treatment with serotonin reuptake inhibitors. J Clin Psychiatry 1997, 58:291-297.